Tarek Haykal, MD, MHS
@TarekHaykal1
Followers
1K
Following
4K
Media
119
Statuses
1K
Assistant professor & medical oncologist at the University of Michigan, immuno-oncology fan, trialist, Melanoma & cutaneous malignancies
Ann Arbor, MI
Joined July 2011
Cemiplimab is now @US_FDA ✅ in adj settings for high risk cutaneous squamous cell cancer based off C-POST study (after ✂️ and XRT): - Improved DFS (HR: 0.32) - At 24mos, mDFS: 87.1% vs 64.1% - Improved local and distant recurrences - New SoC! #OncTwitter #MedEd
0
20
58
It was an absolute pleasure to be part of this high-yield board review course by #MSHO presenting everything one needs to know about Melanoma!
Preparing for your Med-Onc board? Come join us for the MSHO’s 8th Annual Board Review & Recertification Course, taking place at Somerset Inn in Troy, MI on Saturday August 16, 2025. An incredible line-up of speakers from all top institutions in Michigan! https://t.co/YjjcMLLfA5
0
1
15
Preparing for your Med-Onc board? Come join us for the MSHO’s 8th Annual Board Review & Recertification Course, taking place at Somerset Inn in Troy, MI on Saturday August 16, 2025. An incredible line-up of speakers from all top institutions in Michigan! https://t.co/YjjcMLLfA5
0
1
3
Preparing for your Med-Onc board? Come join us for the MSHO’s 8th Annual Board Review & Recertification Course, taking place at Somerset Inn in Troy, MI on Saturday August 16, 2025. An incredible line-up of speakers from all top institutions in Michigan! https://t.co/YjjcMLLfA5
0
1
3
Results from the registrational anti-PD1 melanoma cohort from IGNYTE published in JCO: https://t.co/d30lGx5sOj Stay tuned for possible FDA approval later this month! @Replimune
ascopubs.org
PURPOSEEffective treatment options for melanoma after immune checkpoint blockade failure are limited. RP1 (vusolimogene oderparepvec) is a herpes simplex virus type 1–based oncolytic immunotherapy,...
0
3
7
Happy to share our latest #review on #neoadjuvantimmunotherapy: an extensive overview of current and emerging data in NSCLC, TNBC, GI + bladder cancers, melanoma and many more: written with close friends and KOLs published today in @NatureCancer @lab_kok
https://t.co/HbH5Mm2dvn
nature.com
Nature Cancer - In this Review, Chalabi and colleagues summarize the current clinical landscape of neoadjuvant immunotherapy in solid tumors.
5
61
269
#ASCO25 #melanomaorals 1 year versus 2 years of PD-1 therapy continues to be an important question to answer for our stage 4 patients with melanoma that achieve a response and remain on therapy. Data shared hear looks encouraging though the study was underpowered
0
2
4
#ASCO25 #melanomaorals Upfront Encorafenib/Binimetinib with Nivo has a PFS benefit compared to Ipi/Nivo for patients with symptomatic BRAF mutant metastatic melanoma with Brain mets. No significant differences in OS
0
1
2
#ASCO25 #melanomaorals DREAM-Seq continues to show significant clinical benefit for stage 4 patients with BRAF-mutant melanoma that are treated with upfront Ipi/Nivo vs BRAF/MEK inhibitors, continuing to show IO as the standard for first line systemic therapy
0
1
3
#ASCO25 #melanomaorals Multiple neoadjuvant combination therapies are being explored for high risk resectable stage 3 melanoma, certainly an evolving field! Excited to see how we can bring more effective therapies in this setting to benefit all of our patients!
0
1
3
#ASCO25 #melanomaorals A single dose of Neoadjuvant Pembro for clinical stage 2B and 2C was safe and did not delay surgery, all while it could have a decreased rate of positive SLNBs for some stage 2C melanomas with a potential benefit in RFS and DFMS
0
4
10
#ASCO25 #melanomaorals Adjuvant therapy with Encorafenib (BRAFi) with Binimetinib (MEKi) for high risk resected stage 2B and 2C melanoma could be a potential effective therapy with the known safety profile of this drug combination
0
1
4
#ASCO25 #melanomaorals RELATIVITY-098 showed no RFS benefit in the adjuvant setting of Opdualag for high risk resected stage 3 melanoma, adjuvant PD-1 therapy remains the standard for this patient population
0
0
4
🔔Make sure to check our study!! @ASCO #ASCO25 ⭐️#HighFiber (HF) #diet to modulate microbiome and outcomes in #immunotherapy in #Melanoma ✅ORR: ⬆️HF 77% Cntrl 29% ✅No significant GI related or Immune related AEs with HF diet ✅Cutaneous adverse events⬇️ w HF ✅ impressive EFS
2
31
104
This may be the most discussed abstract @ASCO. Much talk about ivermectin as treatment for cancer, esp on social media. But what are the data? To my knowledge, there are no actual clinical trial data - until now. @nytimes @WSJ @FortuneMagazine @OncoAlert @Larvol
4
16
57
🚨Save the date🚨 @ASCO #IMG Community of Practice Meeting at #ASCO25 ⏰May 30st, 4-6 PM CST 📌Room S103, McCormick Place Join us to discuss barriers & opportunities for IMGs ASCO IMG CoP👉 https://t.co/ke4h9obYok
@ASCOPost #IMGoncCoP #MedEd #MedTwitter
8
42
102
Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study out on JITC https://t.co/XxIRC518fe This retrospective, multicenter study examined the safety and clinical outcomes of 110
1
16
31
‼️Only data so far of ICI in pts with cardiac Mets. Work led by @AminNassarMD @sarahaboualaiwi @TalalZarif1 out in @jitcancer . A collaboration that spanned several countries and centers. @OUCollegeofMed @StephensonCC
@DrChoueiri
https://t.co/NcnmEnozSb
jitc.bmj.com
Background Data on the safety profiles and clinical outcomes of patients with solid tumors and cardiac metastasis treated with immune checkpoint inhibitors (ICIs) are limited.Methods This is an...
Our new paper in @jitcancer with a group of fine international friends, mentees and colleagues about immunotherapy in patients with cardiac metastasis. https://t.co/PeDTs6nsG5
@thenasheffect @AminNassarMD @sarahaboualaiwi @TalalZarif1 @DrRanaMcKay @DanaFarber
0
11
28
Our new paper in @jitcancer with a group of fine international friends, mentees and colleagues about immunotherapy in patients with cardiac metastasis. https://t.co/PeDTs6nsG5
@thenasheffect @AminNassarMD @sarahaboualaiwi @TalalZarif1 @DrRanaMcKay @DanaFarber
jitc.bmj.com
Background Data on the safety profiles and clinical outcomes of patients with solid tumors and cardiac metastasis treated with immune checkpoint inhibitors (ICIs) are limited.Methods This is an...
1
21
44